CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the rate of pathologic complete response when giving
docetaxel and trastuzumab followed by caelyx (liposomal doxorubicin), cyclophosphamide and
trastuzumab before surgery in treating women with operable or locally advanced HER-2 positive
breast cancer.